Hologic’s Tomosynthesis Improves Cancer Detection Rates Of Mammography In Study
This article was originally published in The Gray Sheet
3D breast tomosynthesis improves the recall rate and cancer-detection rate of mammography, according to a retrospective study of 454,850 examinations. The results may be good news for Hologic, which has struggled to accelerate adoption for the technology due to lack of reimbursement.
You may also be interested in...
In a draft recommendation, the U.S. Preventive Services Task Force says evidence is "insufficient" to assess 3D tomosynthesis for breast cancer screening, as well as for additional dense-breast screening by any modality.
Hologic has struggled to gain market acceptance of its 3D breast tomosynthesis technologies because of the lack of reimbursement. But CMS has now delivered a long-awaited surplus rate for 3D compared to 2D scans, which is expected to boost adoption.
GE Healthcare’sSenoClaire breast tomosynthesis system will go head-to-head with Hologic’s 3D mammography system.